Subject Index

The Revised Authoritative Guide To Vaccine Legal Exemptions

Vaccines Have Serious Side Effects

Get Instant Access

acetylation 93,101-103,106 acid-base catalysis 58, 59, 61 acute infection 212, 213, 220 adenosine deaminase that acts on

RNA (ADAR) 7, 17, 215 adenosine deamination 70, 71, 77, 84

164-166 amber/W site 69-84 antigenomic RNA 70, 71 antigenomic RNA replication

29-32, 34-38 antiviral therapy 134,138,141, 142 arginine methylation 30, 35, 37, 104-106

B-cell 193,202-204

budding 116,118-121,123,124,126

catalytic site 56

cellular intermediate compartment

(IC) 116,118,119,125 chronic infection 212, 213,

215-218,220-222 circular RNA 3-5,10,11 clades 156,159-161,165,166 clevudine 221,222 clinical significance 175 crystal structure 51,57,60 cytopathic 188, 190 cytopathic effect 16 cytosine 75 (Cyt75) 49, 51-53

cytotoxic T-cell (CTL) 188,190, 193, 194, 198,200, 201,203,205

delta protein 3,6,16 dicer 15 divalent metal 48 divalent metal ion 52, 55, 60 DNA immunization 188,194, 195, 200-202

editing 2,6-8,17

farnesylation 95, 96, 98, 120,121 farnesyltransferase 94, 95 farnesyltransferase inhibitor (FTI) 139-144

genetic changes 213,215,218,220 genetic variability 155, 156, 160,166

genomic RNA replication 29-32, 34-38

genotype 152,155-157,160, 164-166

genotype I 73-76, 79, 81-84, 134, 139, 155-157, 162, 166, 175, 178-182

genotype II 155-157, 166, 175-181 genotype IIb 155, 156, 160, 164 genotype III 74, 76, 79, 81-84, 134,

139, 155, 157, 162, 164, 166, 167 geography 164, 166 geranylgeranyltransferase 93

HDAg interaction 173, 178, 179 HDV assembly 122,123 HDV infectivity 124-126 hepatitis B surface antigen

(HBsAg) 114 hepatitis B virus (HBV) 114-126,

152, 156, 164-167 hepatitis delta antigen (HDAg)

27-39,92,97-102 hepatitis delta antigen long form (L-HDAg) 68,69,71,74,75, 77-80, 82-84 histone acetyltransferase (HAT) 101, 103

IgM 188, 191, 192

immune response 216-218,220

immunization 188, 194, 195,

198-204 immunogenic domain 204 immunopathogenesis 188, 190,

192,205 in-line orientation 54, 55 inhibition of replication 6, 8 initiation 3,4,9-12,16 inoculum 213-215,217,219,220 interferon 14, 138 isoprenylation 93, 95, 96

kinase 97-100

L-HBsAg 115-119,124-126 lamivudine 138,220,221 large hepatitis delta antigen (L-HDAg) 114, 117, 120-124, 126 linear RNA 3-5,10-12,17

M-HBsAg 115,116,118,119, 124,125

mechanism of transcription 35-38

molecular clone 213, 214

mouse 194

mouse model 138-140

mRNA transcription 33, 34

negative feedback regulation 82 nucleobase 53, 54, 57, 58, 61

phosphorylation 97-100 phylogenetic analysis 156,160 post-translational modification

(PTM) 92, 93, 106, 107 pre-S1 117-119,124 prenylation 134,137, 139-143 prenylation inhibition 138, 139, 141, 142

prenyltransferase 137, 142, 144 protein arginine methyltransferase

(PRMT) 104, 105 pseudoknot structure 50

recombination 13, 14 regulation of editing 77, 80 replication 2-4,6-18,26,28-41,

68-72, 75-84 ribavirin 14

ribonucleoprotein (RNP) 114-117, 120-126 ribozyme 48-61 RNA editing 69-71,79,84, 174,180

RNA packaging 177, 179, 180 RNA polymerase I 26, 40 RNA polymerase II 8, 9,17, 26,

36-38, 40 RNA replication 177-179 RNA secondary structure 160,162

RNA sequence changes 8,16,17 RNA structural dynamics 82, 84 RNA structure 84

S-HBsAg 114-119,121-126 selective pressure 215, 216 sequence comparison 175 siRNA 15

small hepatitis delta antigen (S-HDAg) 114,115,120,121, 124, 162, 166, 167 subcellular localization 96, 101-103

subviral particle (SVP) 115,123,126 surface antigen 212,221

203, 205 template-switching 12, 13, 17 therapy 220-222 transactivation 174,177,179 transmembrane domain (TMD) 117-119, 122, 123

unbranched rod structure 68, 76, 80

vaccination 195,198-203

vaccine 212,213,218,220,222

viral genetics 155,160

virion packaging 71

viroid 11,15,17

virus-like particle (VLP) 138, 139

woodchuck 188-190, 192, 194, 195, 198-203,205,212-214,216-219, 221,222

woodchuck hepatitis virus (WHV) 212-214,221,222

Was this article helpful?

0 0

Post a comment